[Webinar held on 6/15] New AI solution "liGALILEO" for multifaceted scientific evaluation of target molecules-Realizing efficient drug discovery development-
The development of new drugs can be broadly divided into "target search" to search for candidate molecules in the initial phase, "non-clinical studies" using animals, and "clinical studies" to verify efficacy and safety by actually administering to humans. There are three processes, but only 3 / 2 to 3 / 1 of the candidate compounds that are considered to be promising in the initial phase are commercialized, and in addition, they last for a long period of 10 to 15 years. The development period and the enormous development cost of about 1000 billion yen have been regarded as major issues in drug development.
In this seminar, FRONTEO's unique AI technology can be used to perform multifaceted scientific evaluation of candidate substances, enabling the digitization and overwhelming efficiency of the search process, which is important in the initial phase of drug development. Introducing the new AI solution "liGALILEO".
◆ Theme: New AI solution "liGALILEO" for multifaceted scientific evaluation of target molecules-Realizing efficient drug discovery development-
◆ Date: May 2022, 6 (Wednesday) 15: 12-10: 12
・ Those who are considering improving the efficiency of the drug discovery process with AI
・ Those involved in drug discovery research
◆ Participation conditions: Those who use free addresses, those who are in the same industry as our company, and those whose affiliation is unknown are not allowed to apply.When accessing ZOOM on the day of the event, please enter the name and email address you provided when you applied for the ZOOM participation input field.
Keiichiro Yoshimoto
After joining Mitsubishi Tanabe Pharma (formerly Mitsubishi Tanabe Pharma), he engaged in overseas business development and was in charge of out-licensing and marketing of cardiovascular drugs in emerging regions centered on Asia.After that, he was in charge of domestic and overseas business development of functional chemicals at Kao and Sumitomo Chemical, and was assigned overseas as a sales manager. Since 2016, he has participated in the establishment of a pharmaceutical venture company and launched several new businesses as a business manager in the animal health field. He joined FRONTEO in 2021.He is currently working on new business development in the business development team of the Life Science AI Business Headquarters.
Articles in the same category
[Online seminar held on 5/9] New framework and practical outlook for European foreign investment regulations - Explanation of the European Commission's new regulation proposal and the regulatory environment of major countries -
[Real seminar held on 4/18] “Crisis management proposed by a competition law/consumer law boutique firm” ~Risk management to avoid a “crisis”~
Exploring patient stratification biomarkers for IgA nephropathy using AI: Overcoming bias with AI
Parkinson's disease - Analyzing drug discovery targets using paper search AI
Economic Security Symposium co-hosted by FRONTEO x Moody's Analytics Japan on April 4th
Searching for new targets for sporadic ALS using AI: Become friends with AI
[Webinar held on 3/25] Risk of important information leakage of Japanese companies due to cross-border application of discovery and its response
[On-site seminar held on 3/19] Latest trends in AI and competition law - from a global perspective <Simultaneous interpretation and reception available>
[Webinar held on 3/5] Are you fully prepared for a series of information leaks?: Recommendation of mock training from a crisis management perspective
